Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aflibercept + capecitabine
- Development stage
- Phase 2
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Aflibercept + capecitabine is an investigational combination therapy consisting of aflibercept, a recombinant fusion protein that acts as a decoy receptor for vascular endothelial growth factor (VEGF), and capecitabine, an oral prodrug of 5-fluorouracil (5-FU) that inhibits DNA synthesis. Aflibercept blocks angiogenesis by binding VEGF-A, VEGF-B, and placental growth factor (PlGF), thereby preventing these ligands from activating their native receptors on endothelial cells. Capecitabine is converted to 5-FU in the body and interferes with DNA replication in rapidly dividing tumor cells. The combination has been studied primarily in patients with chemorefractory gastrointestinal cancers (including colorectal and gastric cancer) and breast cancer, particularly those unsuitable for more intensive chemotherapy regimens. Clinical trials have demonstrated manageable safety profiles and some anti-tumor activity[2][3][4][5].
- Other names
- ziv-aflibercept
02
Targets
PGF (Placental Growth Factor)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)VEGFB (Vascular endothelial growth factor B)
Beyond the preview
Go deeper on aflibercept + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aflibercept + capecitabine.